PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.
-0.27
Negative OCF/share while Biotechnology median is -0.19. Seth Klarman would examine if a turnaround is realistic.
-0.27
Negative FCF/share while Biotechnology median is -0.21. Seth Klarman would question if the business is too capex-heavy.
No Data
No Data available this quarter, please select a different quarter.
0.80
Ratio 1.25–1.5x Biotechnology median of 0.72. Mohnish Pabrai would confirm that earnings truly convert to cash better than peers.
-9246.91%
Negative ratio while Biotechnology median is -73.12%. Seth Klarman would suspect deeper operational issues or near-zero revenue.